Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bifico with Chemotherapy and Targeted Therapy in Metastatic Colorectal Cancer
NCT04131803Unknown
- Sponsor
- Second Affiliated Hospital of Zhejiang University School of Medicine
- Start
- Oct 2021
- Primary completion
- Nov 2022
- Modality
- Yeast Strains, Defined Consortia, Bacterial Strains
01
Overview
Randomised, open-label trial of bifidobacterium longum/lactobacillus acidophilus/enterococcus faecalis in metastatic colorectal cancer (mCRC), sponsored by Second Affiliated Hospital of Zhejiang University School of Medicine. Primary endpoint: Objective Response Rate at 1 year. Status: unknown.
02
Drugs
bifidobacterium longum/lactobacillus acidophilus/enterococcus faecalis
03
Conditions
metastatic colorectal cancer (mCRC)
Beyond the preview
Go deeper on NCT04131803.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04131803.